MeSH term
Frequency | Condition_Probility | Adult | 28 | 0.0 |
Endoscopy | 11 | 32.0 |
Esophageal and Gastric Varices/surgery/*therapy | 3 | 100.0 |
Humans | 71 | 0.0 |
Ligation | 35 | 50.0 |
Male | 62 | 0.0 |
Adolescent | 11 | 0.0 |
Child | 10 | 0.0 |
Child, Preschool | 7 | 0.0 |
Esophageal and Gastric Varices/mortality/*surgery | 2 | 100.0 |
Esophagoscopy | 12 | 37.0 |
Female | 61 | 0.0 |
Follow-Up Studies | 12 | 0.0 |
Gastrointestinal Hemorrhage/surgery | 2 | 100.0 |
Infant | 4 | 0.0 |
Ligation/instrumentation/methods | 3 | 100.0 |
Liver Transplantation | 2 | 3.0 |
Postoperative Complications | 4 | 2.0 |
Prospective Studies | 19 | 0.0 |
Recurrence | 19 | 1.0 |
Survival Analysis | 6 | 0.0 |
Hemodynamic Processes | 6 | 3.0 |
Portasystemic Shunt, Transjugular Intrahepatic | 3 | 75.0 |
Esophageal and Gastric Varices/*therapy | 8 | 80.0 |
Gastrointestinal Hemorrhage/*therapy | 3 | 100.0 |
*Portal Vein | 2 | 14.0 |
Middle Aged | 48 | 0.0 |
Aged | 28 | 0.0 |
*Esophagoscopy | 8 | 72.0 |
Palliative Care | 2 | 4.0 |
Research Support, Non-U.S. Gov't | 13 | 0.0 |
Survival Rate | 5 | 0.0 |
Hypertension, Portal/*complications | 3 | 75.0 |
Research Support, U.S. Gov't, P.H.S. | 4 | 0.0 |
Sclerotherapy/methods | 2 | 100.0 |
Combined Modality Therapy | 7 | 0.0 |
Comparative Study | 12 | 0.0 |
Esophageal and Gastric Varices/mortality/*therapy | 3 | 100.0 |
*Sclerotherapy | 7 | 63.0 |
Adrenergic beta-Antagonists/therapeutic use | 3 | 4.0 |
Sclerotherapy | 7 | 77.0 |
Gastrointestinal Hemorrhage/etiology | 2 | 28.0 |
Recurrence/prevention & control | 2 | 5.0 |
Treatment Outcome | 12 | 0.0 |
Animals | 2 | 0.0 |
Mice | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
Endoscopy, Gastrointestinal | 4 | 20.0 |
English Abstract | 10 | 0.0 |
Esophageal and Gastric Varices/etiology/*surgery | 5 | 100.0 |
Esophagus/*physiopathology | 4 | 66.0 |
Esophageal and Gastric Varices/etiology/*therapy | 2 | 66.0 |
Liver Cirrhosis/*complications | 2 | 9.0 |
Aged, 80 and over | 6 | 0.0 |
*Embolization, Therapeutic | 2 | 8.0 |
*Endoscopy | 9 | 47.0 |
Esophageal and Gastric Varices/*surgery | 9 | 100.0 |
Splenic Artery | 2 | 40.0 |
Risk Factors | 2 | 0.0 |
Gastrointestinal Hemorrhage/prevention & control/surgery | 2 | 100.0 |
Ligation/methods | 13 | 81.0 |
Esophageal and Gastric Varices/etiology/mortality/*therapy | 2 | 100.0 |
*Hemostasis, Endoscopic | 6 | 100.0 |
Sclerosing Solutions/*therapeutic use | 3 | 75.0 |
Endoscopy/*methods | 3 | 33.0 |
Evaluation Studies | 2 | 0.0 |
Sclerotherapy/adverse effects/*methods | 2 | 100.0 |
Time Factors | 3 | 0.0 |
Esophageal and Gastric Varices/physiopathology/*surgery | 3 | 100.0 |
Liver Cirrhosis/complications | 5 | 15.0 |
Manometry | 3 | 8.0 |
Hypertension, Portal/complications | 5 | 71.0 |
Propranolol/therapeutic use | 2 | 18.0 |
Gastrointestinal Hemorrhage/etiology/*surgery | 3 | 100.0 |
Gastroscopy | 3 | 7.0 |
Prognosis | 2 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
*Endoscopy, Gastrointestinal | 2 | 28.0 |
Laser-Doppler Flowmetry | 2 | 5.0 |
Ligation/adverse effects/*methods | 2 | 100.0 |
Gastric Mucosa/*blood supply | 2 | 100.0 |
Esophagoscopy/methods | 2 | 66.0 |
Ligation/adverse effects | 3 | 60.0 |
Ulcer/etiology | 2 | 100.0 |
Chi-Square Distribution | 2 | 0.0 |
Carcinoma, Hepatocellular/*complications | 2 | 33.0 |
Liver Neoplasms/*complications | 2 | 28.0 |
Esophagoscopes | 3 | 75.0 |
Esophagoscopy/*methods | 4 | 80.0 |
Retrospective Studies | 2 | 0.0 |
Esophageal and Gastric Varices/complications/*surgery | 2 | 100.0 |
